This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Dr. Reddy's (RDY) Earnings & Revenues Trump Estimates in Q2
by Zacks Equity Research
Dr. Reddy's (RDY) earnings and sales beat estimates in second-quarter fiscal 2023.
Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the third quarter of 2022. The company maintains its product revenue guidance for 2022.
Gilead (GILD) Inks Deal for Gene Platform in Blood Cancers
by Zacks Equity Research
Gilead (GILD) signs a license agreement with Refuge Biotechnologies to use the latter's gene expression platform to develop treatments for blood cancers.
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
by Zacks Equity Research
AbbVie (ABBV) acquires UK-based DJS Antibodies Ltd to enhance its antibody research activities and strengthen the immunology portfolio.
Are Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?
by Zacks Equity Research
Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.
Is Akero Therapeutics (AKRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and CymaBay Therapeutics Inc. (CBAY) have performed compared to their sector so far this year.
Altimmune's (ALT) Data From NASH Study Fail to Impress Investors
by Zacks Equity Research
Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.
Biotech Stock Roundup: BMY Surges on Drug Approval, REGN Up on Update & More
by Zacks Equity Research
Regulatory and pipeline updates from BMY and REGN are the key highlights from the biotech sector during the past week.
Akero Therapeutics (AKRO) Up on Positive Data from NASH Study
by Zacks Equity Research
Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.
Akero Therapeutics (AKRO) Up on Positive NASH Study Data
by Zacks Equity Research
Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.
Cigna (CI) to Announce Q2 Earnings: Here's What to Expect
by Zacks Equity Research
Cigna's (CI) second-quarter results are likely to reflect higher pharmacy revenues and a growing customer base.
Is Akero Therapeutics, Inc. (AKRO) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Akero Therapeutics, Inc. (AKRO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.
Wall Street Analysts Think Akero Therapeutics, Inc. (AKRO) Could Surge 92%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Akero Therapeutics, Inc. (AKRO) points to a 91.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Arena (ARNA) Starts Phase II Study on Coronary Drug Temanogrel
by Zacks Equity Research
Arena (ARNA) is developing temanogrel in a phase II study as potential treatment for coronary microvascular obstruction in patients undergoing percutaneous coronary intervention.
Can Akero Therapeutics (AKRO) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Akero Therapeutics (AKRO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Cullinan (CGEM) Rises on Promising Phase I Cancer Study Data
by Zacks Equity Research
Cullinan Oncology (CGEM) is developing its sole pipeline candidate, CLN-081, as a potential treatment for lung cancer in a phase I/IIa study.
Bristol Myers' (BMY) Zeposia Gets FDA Nod for Ulcerative Colitis
by Zacks Equity Research
Bristol Myers (BMY) gets FDA approval for Zeposia to treat adults with moderate-to-severe active ulcerative colitis. This marks the second indication for the drug.
Akero Therapeutics (AKRO) Jumps: Stock Rises 8.9%
by Zacks Equity Research
Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Akero Therapeutics, Inc. (AKRO) Upgraded to Buy: Here's Why
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AKRO) Outperforming Other Medical Stocks This Year?
Moving Average Crossover Alert: Akero Therapeutics
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Is Akero Therapeutics (AKRO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Has Akero Therapeutics (AKRO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (AKRO) Outperforming Other Medical Stocks This Year?
Akero Therapeutics Inc (AKRO) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Akero Therapeutics Inc (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Akero Therapeutics, Inc. (AKRO) a New Buy Stock
by Zacks Equity Research
Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).